OBJECTIVES The study was done to determine whether the G20210A mutation in
the prothrombin gene increases the risk of recurrent venous thromboembolism
(VTE), both alone and in combination with factor V Leiden.
BACKGROUND Several inherited defects of coagulation are associated with inc
reased risk of first VTE, including a recently identified G20210A mutation
in the prothrombin gene. However, whether the presence of this mutation con
fers an increased risk of recurrent venous thromboembolism is controversial
.
METHODS A total of 218 men with incident venous thromboembolism were genoty
ped for the prothrombin mutation and for factor V Leiden and were followed
prospectively for recurrent VTE over a follow-up period of 7.3 years.
RESULTS A total Of 29 men (13.3%) suffered recurrent VTE. Five of the 14 ca
rriers of the prothrombin mutation developed recurrent VTE (35.7%; incidenc
e rate = 8.70 per 100 person-years), while 24 of 204 individuals who did no
t carry the prothrombin mutation developed recurrent VTE (11.8%; incidence
rate = 1.76 per 100 person-years). Thus, presence of the G20210A mutation w
as associated with an approximate fivefold increased risk for recurrent VTE
(crude relative risk [RR] 4.93; 95% confidence interval [CI] 1.9-12.9; p =
0.001; age-, smoking-, and body mass index-adjusted RR 5.28; 95% CI 2.0-14
.0; p = 0.001). In these data, recurrence rates were similar among those wi
th an isolated mutation in the prothrombin gene (18.2%) as compared to thos
e with an isolated factor V Leiden mutation (19.2%). However, all three stu
dy participants who carried both mutations (100%) suffered a recurrent even
t during follow-up.
CONCLUSIONS In a prospective evaluation of 218 men, the presence of prothro
mbin mutation was associated with a significantly increased risk of recurre
nt VTE, particularly among those who co-inherited factor V Leiden. (j Am Co
il Cardiol 2001;37:215-8) (C) 2001 by the American College of Cardiology.